期刊文献+

鼠疫组分疫苗诱导小鼠体液免疫应答研究

Research of humoral immunity response of plague component vaccine in mice
下载PDF
导出
摘要 目的通过检测鼠疫组分疫苗免疫小鼠诱导的体液免疫应答,对其免疫原性进行评价。方法将小鼠随机分成4个实验组,免疫后5周内眦采血,检测血清中抗F1抗原和rV抗原IgG及IgA抗体;充分暴露气管,沿气管上端剪一楔形口,用PBS冲洗肺泡制备肺冲洗液,检测肺冲洗液中抗F1抗原和rV抗原IgG及IgA抗体。结果血清中可产生较高效价的抗F1抗原和rV抗原IgG抗体以及较低效价的抗F1抗原IgA抗体。肺冲洗液中可检测到抗F1抗原和rV抗原的IgG抗体,但无特异性IgA产生。结论鼠疫组分疫苗能诱导小鼠产生较强的血清抗体应答,肺冲洗液可检测到一定的IgG抗体,该疫苗有希望成为我国新一代鼠疫疫苗。 Objective To evaluate the immune response of a new plague component vaccine, which composed of extracted F1 antigen and recombinant V antigen. Methods Mice were randomly divided into four experimental groups, and were tested at five weeks after the first immunization. The blood was collected from each animal by inner canthus. Bronchoalveolar lavage (BAL) was obtained by exposing the trachea and making a small incision. Through this cannula the lungs were repeatedly lavaged by slowly injecting and withdrawing phosphate buffered saline. Individual serum and BAL samples were examined for total anti-F1 and anti-rV IgG and IgA antibodies using ELISA. Results ELISA results showed that plague component vaccine could induce high titer of anti-F1 and anti-rV IgG in the serum, and low titer of anti-F 1 IgA could be detected. Low titer of anti-F 1 and anti-rV IgG rather than IgA could be detected in BAL Conclusion The new plague vaccine can cause significant humoral immunity response in mice, which would be a new generation of plague vaccine.
出处 《中国医药生物技术》 2013年第3期184-187,共4页 Chinese Medicinal Biotechnology
基金 国家高技术研究发展计划(863计划)(2006AA02Z461)
关键词 鼠疫 抗体生成 组分疫苗 F1抗原 rV抗原 Plague Antibody formation Component vaccine F1 antigen Recombinant V antigen
  • 相关文献

参考文献15

  • 1Mizel SB, Graft AH, Sriranganathan N, et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol, 2009, 16(1):21-28.
  • 2Huang J, D'Souza AJ, Alarcon JB, et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol, 2009,16(5):719-725.
  • 3Quenee LE, Ciletti NA, Elli D, et al. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or FI-V vaccines. Vaccine, 2011, 38 (29):6572-6583.
  • 4Quenee LE, Cornelius CA, Ciletti NA, et al. Yersinia pestis caflvariants and the limits of plague vaccine protection. Infect Immun, 2008, 76(5):2025-2036.
  • 5Lin JS, Park S, Adamovicz JJ, et al. TNFa and IFN'y contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague. Vaccine, 2010, 29(2):357-362.
  • 6Koornhof HJ, Smego RA Jr, Nicol M. Yersiniosis. II: The pathogenesis of Yersinia infection. Eur J Clin Microbial Infect Dis, 1999, 18(2):87-112.
  • 7Uppada SB, Bhat AA, Sah A, et al. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice. Vaccine, 2011, 29(50):9352-9360.
  • 8DuBois AB, Freytag LC, Clements JD. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine, 2007, 25(24):4747-4754.
  • 9Williamson ED, Eley SM, Stagg AJ, et al. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine, 1997, 15(10): 1079-1084.
  • 10Motin VL, Nakajima R, Smimov GB, et al. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun, 1994, 62(10):4192-4201.

二级参考文献12

  • 1Baker EE, Sommer H, Foster LE, et al. Studies on immunization against plague. Ⅰ. The isolation and characterization of the soluble antigen of PasteureUa pestis [ J]. J Immunol, 1952, 68 (2) : 131-145.
  • 2Worsham PL, Stein MP, Welkos SL. Construction of defined F1 negative mutants of virulent Yersinia pestis [J]. Contrib Microbiol Immunol, 1995, 13:325-328.
  • 3Une T, Brubaker RR. Roles of V antigen in promoting virulence and immunity in yersiniae [J]. J Immunol, 1984, 133 (4): 2226-2230.
  • 4Anderson GW Jr, Heath DG, Bolt CR, et al. Short- and long-term efficacy of single-dose subunit vaccines against Yersinia pestis in mice [J]. Am J Trop Med Hyg, 1998, 58 (6) :793-799.
  • 5Roggenkamp A, Geiger AM, Leitritz L, et al. Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen [ J ]. Infect Immun, 1997, 65 (2):446-451.
  • 6Williamson ED, Sharp GJ, Eley SM, et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague [J]. Vaccine, 1996, 14 (1718):1613-1619.
  • 7Morris SR. Development of a recombinant vaccine against aerosolized plague [J]. Vaccine, 2007, 25 (16):3115-3117.
  • 8董树林.鼠疫疫苗[M]∥赵铠,章以浩,李河民.医学生物制品学.2版.北京:人民卫生出版社,2007:626-640.
  • 9龙振洲.疫苗的免疫学基础[M]∥赵铠,章以浩,李河民.医学生物制品学.2版.北京:人民卫生出版社,2007:29-80.
  • 10Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes [J]. Nature, 1996, 383 (6603) : 787-793.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部